Although both Al and Fe are bound to transferrin in plasma, they are metabolized differently. Aluminum is less tightly bound to transferrin than is Fe, and might be released in circumstances in which Fe remains bound. The effect of pH and citrate on the binding of 67Ga (a radiotracerused as an analog of Al) to transferrin in normal human serum was tested in the presence of physiological concentrations of CO2. At pH <6.8, Ga started to dissociate from transferrin; at pH 6, >50% of the added 67Ga was present in a low-M, form. In contrast, almost all Fe remained bound to transferrin at pH values as low as 4.7. Citrate at concentrations as great as 100 mmol/L had no effect on binding of Fe, but the binding of 67Ga was markedly reduced at citrate >1 mmol/L. Being bound to transfemn less strongly than Ga is, Al could dissociate even more readily, and loss of Al from transfemn in the kidney might explain why Al but not Fe is excreted in urine.
The potential toxicity of Al in conditions such as renal failure (1) and Alzheimer disease (2, 3) has led to increased interest in the way in which this metal is transported and metabolized within the body. However, a major obstacle to this type of study is the lack of a suitable radioisotope of Al for tracer studies; consequently, Ga, a chemically similar metal with a readily available isotope (67Ga), has been used as an Al analog. A recent study of 67Ga binding to transferrin in Alzheimer patients (4) suggested that the transferrin in such patients might bind Ga (and by implication Al) abnormally. However, we (5) and others (6) have been unable to confirm these findings and suggested that the apparent abnormality ofthe Alzheimer transferrin was due at least in part to the use of methods that caused Ga to dissociate from transferrin.
In our previous study (5), we found that binding of Ga to serum transferrin is much more labile than that of Fe, and may be affected by such factors as dialysis, which removes the bicarbonate needed for metal binding to transferrin (7) , or the degree of Fe saturation.
chelating anion, on the binding of tracer doses of 59Fe and 67Ga to transferrin in human serum. We took care to ensure that physiological concentrations of CO2 were maintained, to prevent loss of bicarbonate. Portions of serum were equilibrated with the C02-enriched air for 18 h and the pH was lowered by adding appropriate amounts of HC1, 1 molIL. The binding of 67Ga and 59Fe was then determined as above. To ensure that the adjustment of pH was carried out rapidly to obviate any appreciable loss of C02, we determined the quantities of HCI required by performing a preliminary experiment in which various amounts of HC1 were added to portions of a C02-equilibrated serum, which were then removed from the incubator and their pH determined without delay.
MaterIals and Methods

Serum
The effect of citrate was determined by adding appropriate amounts of 1 mol/L trisodiuin citrate to portions of C02-equilibrat.ed serum before adding the radioactive tracers.
Results and Discussion
Lowering the pH of serum equilibrated with the 50 milL CO2 had no effect on 59Fe binding, which remained essentially total even down to pH 4.7 (Figure 1) . Binding was rapid, and only at the lowest pH values was binding even slightly increased by incubating the serum with the tracer for 30 mm. In contrast, at pH <7 the proportion of unbound 67( began to increase, and at pH 6.1 less than half was bound, even after 30 mm of At lower pH values, the proportion of bound 67Ga tended to increase again, although a considerable amount still remained in a low-Mr form. The reason for this decrease in the low-Me-associated Ga at pH <6 was not investigated, but could be due to formation of uncharged Ga-citrate complexes, as occurs with Al (9), followed by the binding of these complexes to hydrophobic proteins such as albumin.
Addition of citrate, a competing metal chelator, had no effect on the binding of 59Fe to serum, even when present at 100 mmol/L (Figure 2) . In contrast, binding of Ga was greatly reduced in the presence of 10 mmol/L citrate and almost completely abolished by 100 mmoIJL. Although 10 mmolJL greatly exceeds the normal blood concentrations of citrate (-0.1 mniol/L), in certain situations (e.g., in poorly vascularized tissues) the transferrin:citrate ratio possibly could be decreased to the point where the Ga might start to dissociate.
Thus, although Ga is almost entirely bound to transferrin under normal physiological conditions, the binding is much more labile than that of Fe and is very susceptible to changes in pH or concentrations of competing chelates. Our previous study (5) also demonstrated that changes in the electrolyte composition, even when these do not affect pH or involve addition of other metal chelators, markedly increase the lability of
transferrin-bound
Ga but have no effect on the binding of Fe. Under these conditions, the binding of even tracer amounts of Ga is affected by the degree of iron-saturation of transferrin, whereas the binding of a tracer dose of Fe is not. These results support earlier studies that showed that such changes can induce the release of Ga from purified transferrin (10). One reason for these findings may be the fact that the stability constant for Ga-transferrin (_,1020 L ' mol1) is somewhat lower than that for Fe-transferrin (-10 L mot1) (11 We have previously proposed (5) that if the susceptibility of transferrin-Ga binding to changes in electrolyte and pH is true also for Al, this could explain why Al from serum is normally excreted through the kidney (12) but Fe is not: Local changes in plasma electrolyte composition in the kidney may labilize Al, but not the more tightly bound Fe, thus allowing excretion of Al. A preliminary report (13) of analysis for serum and urinary Al by accelerator mass spectrometry after the administration of a tracer dose of 26Al showed that Al was lost from plasma and excreted in urine much more quickly than was Ga, supporting the suggestion that the affinity of these metals for transferrin plays a key role in explaining certain features of their metabolism.
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